In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
Children are spending more time on their devices than ever before, despite evidence that excessive screen time puts their minds and bodies at risk. Parents should set limits and stick to them — and also change their own online behavior, experts say.
School psychologists provide the first line of treatment for children with mental health issues. Quantifying the shortage depends on who’s counting.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
For Central American migrants who follow U.S. government rules for pursuing asylum, conditions on the Mexican side of the border are sweltering, filled with anxiety and illness. Few people have a clear timetable for when it will get any better.
Many therapists are not familiar with two key treatment options for trauma recommended by the American Psychiatric Association and the Department of Veterans Affairs.
For the seventh year in a row, Missouri will retain its lonely title as the only state without a statewide prescription drug monitoring program. Fears about privacy violations and gun control scuttled the bill yet again, leaving a pastiche of half-step measures in place to fill the void in the fight against prescription drug abuse.
Incidents of serious workplace violence are four times more common in health care than in private industry, according to the Occupational Safety and Health Administration.
In the West and Midwest, 70% of local law enforcement says meth is the bigger threat. It’s also a more difficult addiction to treat.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
